Trials / Completed
CompletedNCT01307033
A Long-term Study of the Safety of MK-0954A in Patients With Essential Hypertension (MK-0954A-351)
A Phase III, Randomized, Active-comparator Controlled and a Long-term Clinical Trial to Study the Safety of MK-0954A (L100/H12.5 mg) in Japanese Patients With Essential Hypertension Uncontrolled With MK-954H (L50/H12.5 mg) [PREMINENT®]
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 278 (actual)
- Sponsor
- Organon and Co · Industry
- Sex
- All
- Age
- 20 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
This study is being conducted to evaluate the safety of MK-0954A (L100/H12.5 mg) in essential hypertension participants who are uncontrolled with MK-954H (L50/H12.5 mg).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | MK-0954A | Tablet containing losartan potassium (100 mg) and hydrochlorothiazide (12.5 mg), once daily |
| DRUG | MK-954H | Tablet containing losartan potassium (50 mg) and hydrochlorothiazide (12.5 mg), once daily |
| DRUG | Placebo to MK-0954A | Placebo tablet to match MK-0954A, once daily |
| DRUG | Placebo to MK-954H | Placebo tablet to match MK-954H, once daily |
Timeline
- Start date
- 2011-03-29
- Primary completion
- 2012-12-04
- Completion
- 2012-12-04
- First posted
- 2011-03-02
- Last updated
- 2024-05-17
- Results posted
- 2014-01-06
Source: ClinicalTrials.gov record NCT01307033. Inclusion in this directory is not an endorsement.